Proliferative Diabetic Retinopathy

In reponse to poor circulation in the retina from diabetic retinopathy, new blood vessels sometimes grow. This is called proliferative diabetic retinopathy.

Does proliferative retinopathy Always Affect Vision?

No it does not always affect vision. It is possible to have advanced, sight threatening, proliferative diabetic retinopathy with normal vision. Proliferative diabetic retinopathy is an advanced for of diabetic eye disease. "Proliferative" means that there is growth, or "proliferation," of abnormal blood vessels in the back of the eye. Sometimes, very severe growth of abnormal blood vessels can also affect the front part of the eye. Proliferative diabetic retinopathy is a marker that diabetes has been present and poorly controlled for a long time. One of the theories that explains why abnormal new blood vessel growth occurs in diabetic eyes is that, as the normal small blood vessels in the eye become diseased and stop working well, the remaining vasculature begins to sprout new abnormal blood vessels. Often there vision is normal when proliferative abnormal blood vessel growth starts, which is one of the reasons it is vital that all diabetics receive regular dilated eye exams.

Proliferative Diabetic Retinopathy Treatment

Treatment for proliferative diabetic retinopathy has evolved over the last several decades. One of the most important aspects of treatment remains optimizing the blood sugar and systemic health in diabetes, since there is no way to completely stop diabetic retinopathy from getting worse when blood sugar, blood pressure, and other vascular diseases are under poor control. The mainstay of eye treatment for proliferative diabetic retinopathy remains a retinal laser procedure, called panretinal photocoagulation (PRP). PRP is performed in the office with either anesthesia drops or an anesthetic injection. It is very well-tolerated by patients, and has been shown repeatedly to reduce the risk of severe vision loss from proliferative diabetic retinopathy. Often, several sessions of panretinal photocoagulation are necessary. It is very important to understand that PRP laser treatment is not a cure for proliferative diabetic retinopathy, as there is no known cure for diabetes or its affects in the body. PRP treatment is very safe, and often helps keep patients from more invasive and extensive surgical procedures. Like every medical procedure, there are potential risks and side-effects to PRP laser. The specific risks and benefits of this type of laser will be discussed with every patient on an individualized basis.

What about Vitrectomy Surgery?

When proliferative diabetic retinopathy is advanced, vitrectomy surgery becomes necessary. That's why screening examinations are important so patients can be treated with laser before the proliferative retinopathy becomes so severe that surgery is necessary. Surgery can substantially reduce the risk of vision loss from severe proliferative diabetic retinopathy, but it does carry a risk from 10 percent to 20 percent of severe vision loss.

Nonclearing vitreous hemorrhage
  Traction retinal detachment involving the macula
  Combined tractional-rhegmatogenous retinal detachment
  Progressive active fibrovascular proliferation
  Macular edema associated with posterior hyaloidal traction
  Dense premacular hemorrhage
  Dense vitreous hemorrhage in the presence of anterior segment neovascularization

What about Anti-VEGF Therapy?

In addition to PRP laser, injectable therapy with anti-vascular endothelial growth factor (VEGF) medications has more recently played a role in the treatment of proliferative diabetic retinopathy. This is, at the moment, not an FDA approved treatment of proliferative retinopathy and is used sometimes to augment the affect of laser, not to replace laser. Since the mid-to-late 2000's, injections into the eye of small molecule antibody drugs have been shown to effectively treat the growth of abnormal new blood vessels. There are a variety of injectable drugs available, and these drugs are sometimes used on their own and are often combined with PRP laser treatment to cause the abnormal new blood vessels to stop growing. The injections are often used before there is extensive growth of abnormal new blood vessels. Injection therapy is administered in the office with either anesthetic drops or an anesthesia injection. It is also well-tolerated by patients, and the eye is often completely comfortable by the morning after the injection procedure. Injectable treatments often have to be repeated, as, with any medicine, the treatment effect of the injections is transient. Injection therapy similar to laser treatment, is very safe. Like any medical procedure, there are potential risks and side-effects to the injections, and these specific issues will be discussed with each patient on an individualized basis. Recently there has been evidence that after intensive injection therapy there is significant reversal of some signs of diabetic retinopathy, and injection therapy can sometimes be given less frequently over time. As injection therapy for proliferative diabetic retinopathy is relatively new, its role in the treatment of abnormal new blood vessels is going to evolve and change over time. Our practice is active in developing the best practices in injection therapy, and we have presented research involving injection dosing in diabetes at the American Society of Retina Specialists meeting in 2013 and 2014.

Proliferative Diabetic Retinopathy NEWS

Below are current articles from a Google News Feed on Proliferative Diabetic Retinopathy

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

MD Magazine

ICO Publishes New Guidelines for Diabetic Retinopathy
MD Magazine
The International Council of Ophthalmology (ICO) published new guidelines for the care of diabetic retinopathy, serving as an updated guide for the screening, referral and follow-up schedules, and appropriate management of vision-threatening variations ...


Highland Mirror

Global Proliferative Diabetic Retinopathy Market 2018 – Merck ...
Highland Mirror
Recent research analysis from ResearchStore.biz with title Proliferative Diabetic Retinopathy Market Research Report 2018 is revealed, offering a ...

and more »

Proliferative Diabetic Retinopathy Market: Anti-VEGF Considered as Effective Management Method for Proliferative ...
364Analyze.com (press release)
Companies in the global proliferative diabetic retinopathy market are employing strategic initiatives that include product development, geographical expansion, acquisitions, and mergers. These strategies are likely to aid the market players in ...


Trinidad & Tobago Express

Don't lose sight of diabetes
Trinidad & Tobago Express
With this in mind, Value Optical has launched its Digital Fundus Photography screening, an effective method of retinopathy screening that is capable of detecting macular oedema and proliferative diabetic retinopathy, the most common causes of vision ...


The Newsman

Proliferative Diabetic Retinopathy (PDR) Market: Identify Key Players and Their Portfolios to Create Effective ...
The Newsman
Proliferative Diabetic Retinopathy (PDR) Market Pipeline Review, H1 2018, latest report provides report provides a snapshot of the global therapeutic landscape of Proliferative Diabetic Retinopathy (PDR), Key players involved with pipeline review and ...


Diabetic Retinopathy Market| GLOBAL INDUSTRY ANALYSIS AND FORECAST TO 2024
The Newsman
Browse key industry insights spread across 90 pages with 53 market data tables & 10 figures & charts from the report, “Diabetic Retinopathy Market Size By Type (Proliferative Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy), By Management ...


India: United States Food And Drug Administration Permits Marketing Of First Artificial Intelligence Based Device
Mondaq News Alerts
IDx-DR is intended for use by health care providers, to automatically detect more than mild diabetic retinopathy (mtmDR) in adults (22 years of age or older) diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy ...

and more »

Artificial intelligence corrals diabetic maculopathy in the developing world
Healio (blog)
Eyenuk analyzes each picture for patterns suggesting either diabetic retinopathy or proliferative disease. Photos are categorized as being low, medium or high risk. This information is relayed to the caregivers (technicians or non-surgical eye doctors ...


Long-Term Type 1 Diabetes Associated With Cognitive Decline
Monthly Prescribing Reference
Cardiovascular disease was associated with decreased executive function and proliferative diabetic retinopathy with slower psychomotor speed among Medalists. "Although both groups with diabetes showed similar deficit patterns, the underlying ...


Hyperglycemia, not insulin resistance, influences cognitive decline in type 1 diabetes
Healio
Within the Medalist cohort, 34.6% had cardiovascular disease, 41.9% had proliferative diabetic retinopathy and 4.9% had diabetic nephropathy. The mean Wechsler Abbreviated Scale of Intelligence scores were 120.3 for controls, 117.1 for patients with ...


Decades of type 1 diabetes linked to mild drop in cognition
Science Daily
Medalists on average performed slightly worse than those without diabetes. This diminished performance was associated with proliferative diabetic retinopathy, an advanced form of eye disease. (However, it didn't reflect poorer vision, since Medalists ...


The Camping Canuck (press release) (blog)

Diabetic Retinopathy Market Opportunity Assessment, Market Challenges, Key vendor analysis, Vendor landscape by ...
The Camping Canuck (press release) (blog)
Non-proliferative diabetic retinopathy market has been registered to have been dominant in 2016, a trend that is predicted to continue over 2017-2024. Proliferated diabetic retinopathy, on the other hand, is a severe stage of the disorder that can lead ...


IRIDEX Co. (IRIX) Given Consensus Recommendation of “Strong Buy” by Analysts
StockNewsTimes
... 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic ...

and more »

Market Assessment

Global Proliferative Diabetic Retinopathy Therapeutics Market 2018-2025 PanOptica Inc, ThromboGenics NV, Aerie ...
Market Assessment
Global market study ” Proliferative Diabetic Retinopathy Therapeutics Market ” in-depth Research of the Proliferative Diabetic Retinopathy Therapeutics market state and the competitive landscape globally. It analyses the important factors of the ...

and more »

Vitreous Tamponades Market to Attract a Revenue of US$ 89.9 Million by the End of 2025
theperfectinvestor.com
As per statistics of the American Academy of Ophthalmology, 17 million cases of proliferative diabetic retinopathy were recorded globally in 2013. Diabetic retinopathy exclusively requires vitrectomy, which in turn, is stoking demand for vitreous ...

and more »

Proliferative Diabetic Retinopathy Therapeutics Market Performance In 2018 And 2025
The Financial
Proliferative Diabetic Retinopathy Therapeutics market report enlists several important factors, starting from the basics to advanced market intelligence which plays a crucial part in strategizing. A thorough analysis is provided for each region based ...


KTVN

Ask the Doctor: Eye Health for Diabetics
KTVN
Proliferative retinopathy is when blood vessels leak into the center of your eye. Blurry vision is one of the signs that this is happening. You may also experience spots or floaters, or have trouble with night vision. 3) HOW DOES HYPERTENSION IMPACT ...


IRIDEX CORPORATION (NASDAQ:IRIX) Files An 8-K Submission of Matters to a Vote of Security Holders
Market Exclusive
In addition, the Company's ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require ...
IRIDEX (NASDAQ:IRIX) versus Trimedyne (TMED) Head to Head ContrastWeek Herald

all 2 news articles »

ScienceBlog.com (blog)

Dental researchers identify protein key to wound healing
ScienceBlog.com (blog)
Blocking Foxo1 could work in cases where reduced angiogenesis would be helpful, like in patients with tumors or diabetic retinopathy.” The study was recently highlighted in a commentary article in the journal as an important finding. Jeon conducted the ...


Aerpio Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
Bristol Herald Courier (press release) (blog)
CINCINNATI--(BUSINESS WIRE)--May 31, 2018--Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, ...


Type 1 diabetes linked to mild drop in cognition: Study
Business Standard
Participants on average performed slightly worse than those without diabetes, the researcher said. This diminished performance was associated with proliferative diabetic retinopathy, an advanced form of eye disease. However, it didn't reflect poorer ...

and more »

Proliferative Diabetic Retinopathy Market Pipeline Review H1 Development by Therapy Area, Stage of Development ...
The Financial
Proliferative Diabetic Retinopathy market Pipeline Review, H1 2018 report delivers the Proliferative Diabetic Retinopathy latest Pharmaceutical and Healthcare disease pipeline guide, therapeutics under complete with analysis by stage of development ...


The Indian Express

Diabetic Retinopathy: Why blurred vision should raise red flags for diabetics
The Indian Express
Abnormal retinal blood vessels bleeding causes the appearance of wavy vision and colour changes. When blood vessels leak into the centre of the eye, it is identified as Proliferative Retinopathy. Blurry vision is one of the signs along with spots or ...


Frisco Fastball

Ohr Pharmaceutical Inc (NASDAQ:OHRP) Q1 2018 Sentiment Report
Frisco Fastball
The firm is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. The stock decreased 3.93% or $0.0098 during the last ...

and more »

Regeneron Pharmaceuticals, Inc. (REGN) Is At $327.07 Formed Wedge; Claar Advisors Has Boosted Comcast New ...
Thorold News
... INJECTION DEMONSTRATES POSITIVE TOPLINE RESULTS IN PHASE 3 NON-PROLIFERATIVE DIABETIC RETINOPATHY TRIAL; 16/05/2018 – Sanofi's Dupixent Drug Meets Endpoints for Atopic Dermatitis Treatment; 19/03/2018 – NOVARTIS NOVN.

and more »

StockNewsTimes

Head to Head Survey: IRIDEX (IRIX) and Edap Tms (NASDAQ:EDAP)
StockNewsTimes
... 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic ...

and more »

Dove Medical Press

Subthreshold microsecond laser for proliferative diabetic retinopathy: a randomized pilot study
Dove Medical Press
Methods: In this randomized, prospective, pilot study, 20 eyes of 10 subjects with symmetric severe non-proliferative (NPDR) or low-risk proliferative diabetic retinopathy (PDR) were included. Each eye of the subject was randomized into either CWL or ...


Somewhat Positive News Coverage Somewhat Unlikely to Affect IRIDEX (NASDAQ:IRIX) Share Price
StockNewsTimes
... 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic ...


Propranolol for Proliferative Diabetic Retinopathy
Healio
Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology. 1981;88(7):583–600. Gross JG ...


Proliferative Diabetic Retinopathy Market to Grow at 9.5% CAGR through 2026
The Financial
The global proliferative diabetic retinopathy market is likely to grow at a CAGR of 9.5% during the assessment period 2017-2026, on account of a range of macroeconomic and industry-specific factors. According to the report, the proliferative diabetic ...

» Load more